Oral administration of curcumin suppresses production of matrix metalloproteinase (MMP)-1 and MMP-3 to ameliorate collagen-induced arthritis: Inhibition of the PKCδ/JNK/c-Jun pathway

Journal of Pharmacological Sciences

Volumn 111, Issue 1, 2009, Pages 13-21

  Se, Hwan Mun ^a   Hyuk, Soon Kim ^a   Jie, Wan Kim ^a   Na, Young Ko ^a   Do, Kyun Kim ^a   Beob, Yi Lee ^a   Kim, Bokyung ^a   Hyung, Sik Won ^a   Shin, Hwa Sup ^a   Han, Jeung Whan ^b   Hoi, Young Lee ^c   Young, Mi Kim ^d   Wahn, Soo Choi ^a  

^a Konkuk University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Konyang University   (South Korea)

^d Duksung Women's University   (South Korea)

Author keywords

Collagen induced arthritis; Curcumin; Matrix metalloproteinase (MMP) 1; MMP 3; Protein kinase C (PKC )

Indexed keywords

COLLAGEN; CURCUMIN; INDOMETACIN; INTERSTITIAL COLLAGENASE; PROTEIN KINASE C GAMMA; ROTTLERIN; STRESS ACTIVATED PROTEIN KINASE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BONE EROSION; CARTILAGE CELL; CARTILAGE DEGENERATION; CONTROLLED STUDY; DRUG MECHANISM; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ADMINISTRATION, ORAL; ANIMALS; ARTHRITIS, EXPERIMENTAL; CELLS, CULTURED; CHONDROCYTES; CURCUMIN; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; JOINTS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MICE; MICE, INBRED DBA; PHOSPHORYLATION; PROTEIN KINASE C-DELTA; PROTO-ONCOGENE PROTEINS C-JUN; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE;

EID: 70349501979     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09134FP     Document Type: Article

References (41)

1. Pari L, Tewas D, Eckel J. Role of curcumin in health and disease. Arch Physiol Biochem. 2008;114:127-149.
2. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65:1631-1652.
3. Funk JL, Frye JB, Oyarzo JN, Kuscuoglu N, Wilson J, McCaffrey G, et al. Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis. Arthritis Rheum. 2006;54:3452-3464. (Pubitemid 44737157)
4. Mor A, Abramson SB, Pillinger MH. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol. 2005;115:118-128. (Pubitemid 40693079)
5. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford). 2006;45:669-675. (Pubitemid 43985334)
6. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356-361.
7. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2006;103:3298-3303. (Pubitemid 43346464)
8. Mun SH, Kim JW, Nah SS, Ko NY, Lee JH, Kim JD, et al. TNF-α-induced IL-32 is positively regulated via the Syk/ protein kinase Cδ/JNK pathway in rheumatoid synovial fibroblasts. Arthritis Rheum. 2009;60:678-685.
9. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. 1995;38:151-160.
10. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529-543.
11. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001;108:73-81. (Pubitemid 32634924)
12. Liacini A, Sylvester J, Li WQ, Zafarullah M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor κB (NF-κB) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol. 2002;21:251-262. (Pubitemid 34497016)
13. Simmonds RE, Foxwell BM. Signalling, inflammation and arthritis NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford). 2008;47:584-590.
14. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor In chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071. (Pubitemid 27163860)
15. Dhandapani KM, Mahesh VB, Brann DW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem. 2007; 102:522-538.
16. Cho JW, Park K, Kweon GR, Jang BC, Baek WK, Suh MH, et al. Curcumin inhibits the expression of COX-2 in UVBirradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential upstream targets. Exp Mol Med. 2005;37:186-192. (Pubitemid 40992733)
17. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experi-mental model of arthritis. J Exp Med. 1997; 146:857-868.
18. Brahn E, Banquerigo ML, Firestein G, Boyle DL, Salzman AL, Szabo C. Collagen induced arthritis: reversal by mercaptoethylguanidine, a novel anti-inflammatory agent with a combined mechanism of action. J Rheumatol. 1998;25:1785-1793. (Pubitemid 28439274)
19. Ono Y, Inoue M, Mizukami H, Ogihara Y. Suppressive effect of Kanzo-bushi-to, a Kampo medicine, on collagen-induced arthritis. Biol Pharm Bull. 2004;27:1406-1413. (Pubitemid 41701684)
20. Takayanagi H, Oda H, Yamamoto S, Kawaguchi H, Tanaka S, Nishikawa T. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun. 1997;240:279-286. (Pubitemid 27523651)
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage t4. Nature. 1970;227: 680-685.
22. Yoshihara Y, Yamada H. Matrix metalloproteinases and cartilage matrix degradation in rheumatoid arthritis. Clin Calcium. 2007;17:500-508.
23. Feng X. Regulatory roles and molecular signaling of TNF family members in osteoclasts. Gene. 2005;350:1-13. (Pubitemid 40503139)
24. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81:807-869. (Pubitemid 32267078)
25. Engsig MT, Chen QJ, Vu TH, Pedersen AC, Therkidsen B, Lund LR, et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol. 2000;151:879-889. (Pubitemid 30945464)
26. Reuben PM, Brogley MA, Sun Y, Cheung HS. Molecular mechanism of the induction of metalloproteinases 1 and 3 in human fibroblasts by basic calcium phosphate crystals. Role of calcium-dependent protein kinase C alpha. J Biol Chem. 2002; 277:15190-15198. (Pubitemid 34952598)
27. Kim Y, Lee YS, Choe J, Lee H, Kim YM, Jeoung D. CD44- epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. J Biol Chem. 2008;283: 22513-22528.
28. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-916. (Pubitemid 32224400)
29. Larsen C, Ostergaard J, Larsen SW, Jensen H, Jacobsen S, Lindegaard C, et al. Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders. J Pharm Sci. 2008;97:4622-4654.
30. Vonkeman HE, van de Laar MA. NSAIDs: adverse effects and their prevention. Semin Arthritis Rheum 2008;doi:10.1016 / j.semarthrit. 2008.08.001.
31. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59:1074-1081.
32. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001; 358:903-911.
33. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48:319-324.
34. Lee JH, Kim JW, Ko NY, Mun SH, Her E, Kim BK, et al. Curcumin, a constituent of curry, suppresses IgE-mediated allergic response and mast cell activation at the level of Syk. J Allergy Clin Immunol. 2008;121:1225-1231.
35. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum. 2000;43:2619-2633. (Pubitemid 32001727)
36. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999;27:486-494.
37. Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev. 2002;11:535-540. (Pubitemid 34615160)
38. Satoskar R, Shah SJ, Shenoy SG. Evaluation of antiinflammatory property of curcumin (diferuloylmethane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol. 1986;24:651-654. (Pubitemid 17205963)
39. Dhillon N, Wolff RA, Abbruzzese JL, Hong D, Camacho L, Li L, et al. Phase II clinical trial of curcumin in patients with advanced pancreatic cancer: 2006 ASCOAnnual Meeting Proceedings. J Clin Oncol. 2006;24:141-151.
40. Shankar T, Shantha NV, Ramesh HP, Murthy IA, Murthy VS. Toxicity studies on turmeric (Curcuma longa): Acute toxicity studies in rats, guinea pigs and monkeys. Indian J Exp Biol. 1980;18:73-75. (Pubitemid 10143537)
41. Soni K, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol. 1992;36:273-275. (Pubitemid 23031285)